Open-Label Lesinurad Monotherapy Extension Study in Gout

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

August 31, 2014

Conditions
Gout
Interventions
DRUG

lesinurad

Tablets, 400 mg QD

Trial Locations (75)

1023

Grafton

3143

Tauranga

3600

Genk

4029

Herston

4092

Silverglen

5530

Yvoir

6534

Gozée

7000

Hobart

7600

Stellenbosch

7700

Rondebosch

8500

Kortrijk

10016

New York

11201

Brooklyn

12553

New Windsor

18960

Sellersville

19046

Jenkintown

19446

Landsdale

23235

Richmond

23320

Chesapeake

23435

Suffold

26505

Morgantown

27103

Winston-Salem

27612

Raleigh

28602

Hickory

29303

Spartanburg

29588

Myrtle Beach

30265

Newnan

33143

Miami

33472

Boynton Beach

33563

Plant City

33607

Tampa

33880

Winter Haven

35209

Birmingham

35211

Birmingham

35294

Birmingham

37027

Brentwood

37174

Spring Hill

38654

Olive Branch

39202

Jackson

40504

Lexington

42701

Elizabethtown

43551

Perrysburg

44130

Middleburg Heights

45242

Cincinnati

49684

Traverse City

58103

Fargo

70006

Metairie

75235

Dallas

77098

Houston

80113

Englewood

80220

Denver

80230

Denver

80922

Colorado Springs

83646

Meridian

84010

Bountiful

84041

West Layton

85282

Tempe

85308

Glendale

85381

Peoria

87106

Albuquerque

90255

Huntington Park

91723

Covina

92618

Irvine

95608

Carmichael

96814

Honolulu

98104

Seattle

99208

Spokane

06611

Trumbill

M9W 4L6

Toronto

G1V 3M7

Québec

G5L 8W1

Rimouski

01069

Dresden

04109

Leipzig

0002

Muckleneuk

0380

Thabazimbi

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY